IL17A and cancer: The KEGG pathway enrichment demonstrated significant enrichment of DEGs in interleukin 17 (IL-17) signaling pathway, T helper 17 (Th17) cell differentiation, malaria, African trypanosomiasis, nuclear factor κB (NF-κB) signaling pathway, rheumatoid arthritis, advanced glycation end products (AGEs)-receptor for AGE (RAGE) signaling pathway in diabetic complications, tumor necrosis factor (TNF) signaling pathway, transcriptional misregulation in cancer, pertussis among others (see Supplementary File 4B).